

-.MELISSA ZULLI 3 BANK STREET ASCOT VALE VIC 3032

LACHLAN STACEY 14-Aug-2013 Male

698 FIG TREE POCKET ROAD FIG TREE POCKET QLD 4069

LAB ID : 4026836 UR NO. : 6647919 Collection Date : 23-Sep-2024 Received Date: 24-Sep-2024



4026836

COMPLETE MICROBIOME MAPPING

General Macro	scopic Descriptio	n
	Result	Markers
Stool Colour	Brown	Colour - Brown is the colour of normal stool. Other colours may indicate abnormal gut health.
Stool Form	Semi-formed	Form -Sample form is categorised using the Bristol stool chart. A comment on stool appearance can be found in the comments section.
Mucous	Not Detected	Mucous - Mucous production may indicate the presence of an infection and/or inflammation.
Occult Blood	Negative	Blood (Macro) - The presence of blood in the stool may be the result of several causes besides colorectal bleeding, including hemorrhoids or gastrointestinal infection.

Short Chain Fatty Acids	Result	Range	Units	
Methodology: GC/MS				
Short Chain Fatty Acids, Beneficial	53.5	> 13.6	umol/g	•
Butyrate	24.0	10.8 - 33.5	%	•
Acetate	62.8	44.5 - 72.4	%	•
Propionate	11.2	0.0 - 32.0	%	•
Valerate	2.0	0.5 - 7.0	%	

GIT Functional Markers	Result	Range	Units	
Methodology: FEIA, EIA, CLIA, pH electrode				
Calprotectin.	<5.0	0.0 - 50.0	ug/g	
Pancreatic Elastase	>800.0	> 200.0	ug/g	
Secretory (slgA)	761.2	510.0 - 2040.	0 ng/mL	•
Zonulin	44.1	0.0 - 107.0	ng/mL	
Beta glucuronidase	<i>6602.0</i> *H	368.0 - 6266.	0 U/g	•
Steatocrit	<i>14.0</i> *H	0.0 - 10.0	%	
a-Transglutaminase IgA	<20	0.0 - 100.0	units/L	•
pH	6.8	6.3 - 7.7		•

Microbiome Mapping Summary

Relative Commensal Abundance of the 6 Phyla groups can be found on page 5 of this report

Printed: 02/Oct/24 10:19



-. MELISSA ZULLI **3 BANK STREET ASCOT VALE VIC 3032**

LACHLAN STACEY 14-Aug-2013 Male

698 FIG TREE POCKET ROAD **FIG TREE POCKET QLD 4069**

4026836 LAB ID: UR NO.: 6647919 Collection Date : 23-Sep-2024 **Received Date:** 24-Sep-2024



Parasites and Worms.	Result	Range	Units		
Parasitic Organisms					
Cryptosporidium species	<dl< td=""><td>< 1.0</td><td>x10^5 org/g</td><td></td><td></td></dl<>	< 1.0	x10^5 org/g		
Entamoeba histolytica.	<dl< td=""><td>< 1.0</td><td>x10^5 org/g</td><td></td><td></td></dl<>	< 1.0	x10^5 org/g		
Giardia intestinalis	<dl< td=""><td>< 1.0</td><td>x10^5 org/g</td><td></td><td></td></dl<>	< 1.0	x10^5 org/g		
Blastocystis hominis.	<dl< td=""><td>< 1.0</td><td>x10^5 org/g</td><td></td><td></td></dl<>	< 1.0	x10^5 org/g		
Dientamoeba fragilis.	<dl< td=""><td>< 1.0</td><td>x10^5 org/g</td><td></td><td></td></dl<>	< 1.0	x10^5 org/g		
Endolimax nana	<dl< td=""><td>< 1.0</td><td>x10^5 org/g</td><td></td><td></td></dl<>	< 1.0	x10^5 org/g		
Entamoeba coli.	<dl< td=""><td>< 5.0</td><td>x10^5 org/g</td><td></td><td></td></dl<>	< 5.0	x10^5 org/g		
Pentatrichomonas hominis	<dl< td=""><td>< 1.0</td><td>x10^5 org/g</td><td></td><td></td></dl<>	< 1.0	x10^5 org/g		
Worms					
Ancylostoma duodenale, Roundwori	m Not Dete	ected			
Ascaris lumbricoides, Roundworm	Not Dete	ected	Necator an	nericanus, Hookworm	Not Detected
Trichuris trichiura, Whipworm	Not Dete	ected		vermicularis,Pinworm	Not Detected
				-,	

Enterocytozoon spp Not Detected Strongyloides spp, Roundworm **Not Detected** Hymenolepis spp, Tapeworm Taenia species, Tapeworm

Not Detected Not Detected

Comment: Not Detected results indicate the absence of detectable DNA in the sample for the worms reported. NOTE: Reflex testing is performed on clinically indicated samples

Opportunistic Bacteria/Overgrow	th Result	Range	Units
Bacillus species.	0.14	< 1.00	x10^4 CFU/g
Enterococcus faecalis	0.92	< 1.00	x10^5 CFU/g
Enterococcus faecium	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td></dl<>	< 1.00	x10^5 CFU/g
Morganella species	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td></dl<>	< 1.00	x10^5 CFU/g
Pseudomonas species	<dl< th=""><td>< 1.00</td><td>x10^4 CFU/g</td></dl<>	< 1.00	x10^4 CFU/g
Pseudomonas aeruginosa.	<dl< th=""><td>< 3.00</td><td>x10^4 CFU/g</td></dl<>	< 3.00	x10^4 CFU/g
Staphylococcus species	0.15	< 1.00	x10^3 CFU/g
Staphylococcus aureus	<dl< th=""><td>< 5.00</td><td>x10^3 CFU/g</td></dl<>	< 5.00	x10^3 CFU/g
Streptococcus agalactiae.	<dl< th=""><td>< 3.00</td><td>x10^4 CFU/g</td></dl<>	< 3.00	x10^4 CFU/g
Streptococcus anginosus.	<dl< th=""><td>< 1.00</td><td>x10^6 CFU/g</td></dl<>	< 1.00	x10^6 CFU/g
Streptococcus mutans.	<dl< th=""><th>< 1.00</th><th>x10^4 CFU/g</th></dl<>	< 1.00	x10^4 CFU/g
Streptococcus oralis.	0.12	< 1.00	x10^6 CFU/g
Streptococcus salivarius.	0.22	< 5.00	x10^6 CFU/g
Methanobrevibacter smithii	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td></dl<>	< 1.00	x10^5 CFU/g
Desulfovibrio piger	<dl< th=""><td>< 18.00</td><td>x10^6 CFU/g</td></dl<>	< 18.00	x10^6 CFU/g
Enterobacter cloacae complex.	<dl< th=""><td>< 5.00</td><td>x10^5 CFU/g</td></dl<>	< 5.00	x10^5 CFU/g
Potential Autoimmune Triggers	الم	< 5.00	MOM CELIA
Citrobacter species.	<dl< th=""><th></th><th>x10^4 CFU/g</th></dl<>		x10^4 CFU/g
Citrobacter freundii.	<dl< th=""><th>< 5.00</th><th>x10^4 CFU/g</th></dl<>	< 5.00	x10^4 CFU/g
Klebsiella species	<i>5.68</i> *H		x10^3 CFU/g
Klebsiella pneumoniae.	<i>5.79</i> *H	< 5.00	x10^5 CFU/g
Prevotella copri	<dl< th=""><th>< 1.00</th><th>x10^9 CFU/g</th></dl<>	< 1.00	x10^9 CFU/g
Proteus species	<dl< th=""><th>< 5.00</th><th>x10^5 CFU/g</th></dl<>	< 5.00	x10^5 CFU/g
Proteus mirabilis.	<dl< th=""><th>< 1.00</th><th>x10^4 CFU/g</th></dl<>	< 1.00	x10^4 CFU/g
Fusobacterium species	1.39	< 10.00	x10^4 CFU/g



-.MELISSA ZULLI 3 BANK STREET ASCOT VALE VIC 3032

LACHLAN STACEY 14-Aug-2013 Male

698 FIG TREE POCKET ROAD FIG TREE POCKET QLD 4069

LAB ID: 4026836 UR NO.: 6647919 Collection Date: 23-Sep-2024 Received Date: 24-Sep-2024



Printed: 02/Oct/24 10:19

4026836

			le. 24-3eμ-2024	
ycology	Result	Range	Units	
Candida dubliniensis.	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
Candida glabrata.	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
Candida intermedia.	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
Candida krusei.	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
Candida lambica.	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
Candida lusitaniae.	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
Candida parapsilosis.	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
Candida albicans.	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
Candida famata.	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
Candida keyfr.	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
Candida lipolytica.	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
Geotrichum species.	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
Rhodotorula species.	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
Saccharomyces cerevisiae:	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
acterial Pathogens	Result	Range	Units	
Aeromonas hydrophila.	<dl< th=""><th>< 1.00</th><th>x10^3 CFU/g</th><th></th></dl<>	< 1.00	x10^3 CFU/g	
Campylobacter species.	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
C. difficile, Toxin A	<dl< th=""><th>< 1.00</th><th>x10^4 CFU/g</th><th></th></dl<>	< 1.00	x10^4 CFU/g	
C. difficile, Toxin B	<dl< th=""><th>< 1.00</th><th>x10^4 CFU/g</th><th></th></dl<>	< 1.00	x10^4 CFU/g	
Enterohemorrhagic E. coli	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
Enteroinvasive E. coli/Shigella	<dl< th=""><th>< 1.00</th><th>x10^3 CFU/g</th><th></th></dl<>	< 1.00	x10^3 CFU/g	
Enterotoxigenic E. coli LT/ST	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
Shiga-like Toxin E. coli stx1	<dl< th=""><th>< 1.00</th><th>x10^4 CFU/g</th><th></th></dl<>	< 1.00	x10^4 CFU/g	
Shiga-like Toxin E. coli stx2	<dl< th=""><th>< 1.00</th><th>x10^4 CFU/g</th><th></th></dl<>	< 1.00	x10^4 CFU/g	
Salmonella species.	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
Vibrio species.	<dl< th=""><th>< 1.00</th><th>x10^4 CFU/g</th><th></th></dl<>	< 1.00	x10^4 CFU/g	
Yersinia species.	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
Helicobacter pylori	<dl< th=""><th>< 1.0</th><th>x10^3 CFU/g</th><th></th></dl<>	< 1.0	x10^3 CFU/g	
Comment: Helico Pylori virulence	factors	will be liste	ed below if detected POSITIV	E
H.pylori Virulence Factor, babA	Not Det	ected	H.pylori Virulence Factor, cagA	Not Detected
H.pylori Virulence Factor, dupA	Not Det	ected	H.pylori Virulence Factor, iceA	Not Detected
H.pylori Virulence Factor, oipA	Not Det		H.pylori Virulence Factor, vacA	Not Detected
H.pylori Virulence Factor, virB	Not Det	ected	H.pylori Virulence Factor, virD	Not Detected
iral Pathogens	Result	Range	Units	

GIT Functional markers performed by GCMS,EIA,FEIA.

Adenovirus 40/41

Sapovirus (I,II,IV,V)

Astrovirus (hAstro)

Norovirus GI/II

Rotavirus A

 ${\tt Bacteriology, Virology, Fungi, Parasites~\&~Worms~performed~by~PCR, qPCR~\&~MALDI-TOF.}$

AST performed by Vitek 2 System, M50 Phoenix Microbial Antibiotic susceptibility, Manual Minimum Inhibition Concentration. <dl = result below detectable limit. *H = Result greater than the reference range. *L = Result less than the reference range</pre>

Not Detected

Not Detected

Not Detected

Not Detected

Not Detected



-. MELISSA ZULLI **3 BANK STREET ASCOT VALE VIC 3032**

LACHLAN STACEY 14-Aug-2013 Male

698 FIG TREE POCKET ROAD **FIG TREE POCKET QLD 4069**

LAB ID: 4026836 UR NO.: 6647919 Collection Date: 23-Sep-2024 Received Date: 24-Sep-2024



4026836

Normal Bacterial GUT Flora	Result Range	Units
Bacteroides fragilis	0.6 * L 1.6 - 250.0	x10^5 CFU/g
Bifidobacterium adolescentis	<dl*l -="" 1000.0<="" 4.6="" td=""><td>x10^5 CFU/g</td></dl*l>	x10^5 CFU/g
Bifidobacterium bifidum.	<d/*L 4.6 - 1000.0</d	x10^6 CFU/g ●
Bifidobacterium breve.	<d/*L 4.6 - 1000.0</d	x10^3 CFU/g ●
Bifidobacterium longum	9.0 4.6 - 1000.0	x10^4 CFU/g
Enterococcus species	9.7 1.9 - 2000.0	x10^3 CFU/g ●
Escherichia species	400.0 3.7 - 3800.0	x10^4 CFU/g
Lactobacillus acidophilus.	<d/*L 1.7 - 500.0</d	x10^3 CFU/g ●
Lactobacillus casei.	12.3 1.7 - 500.0	x10^3 CFU/g
Lactobacillus delbrueckii	3.0 1.7 - 500.0	x10^3 CFU/g
Lactobacillus plantarum.	<d/[∗]L 1.7 - 500.0</d	x10^3 CFU/g ●
Lactobacillus rhamnosus	<d/*L 1.7 - 500.0</d	x10^3 CFU/g ●
Lactobacillus salivarius	<d/*L 1.7 - 500.0</d	x10^3 CFU/g ●
Clostridium species	21.6 5.0 - 50.0	x10^7 CFU/g
Oxalobacter formigenes	<d/*L > 5.00</d	x10^6 CFU/g ●
Akkermansia muciniphila	<d/*L 1.00 - 50.00</d	x10^7 CFU/g
Faecalibacterium prausnitzii	294.5 200.0 - 3500.	0 x10^6 CFU/g

Actions	L. plantarum HEAL9	L. paracasel 8700:2	L. plantarum HEAL19	L. plantarum 6595	L. plantarum 299V	L. rhamnosus GG	L. acidophilus LA02	animals subsp. lactis BS01	L. casei LC03	B. breve BR03	L. fermentum LF08	L. crispatus strains	animals subsp. lactis BA05	L. plantarum LP01	L. rhamnosus LR06	B. longum 04	L. fermentum LF16	L. salivarius LS01	B. breve B632	L. fermentum LF10	L. salivarius LS03	L. helveticus Rosell-52	L. rhamnosus Rosell-11	B. longums Rosell-75	boulardii CNCM I-1079	S. thermophilus FP4
Intestinal epithelial barrier health				•	•	•			•	•								•				•	•		•	
Mucous membrane health				•		•																	•		•	
Normalisation of bowel movements					•	•	•	•		•				•								•				
Normalisation of bloating					•	•	•	•		•				•												
Normalisation of peristalsis					•	•	•	•		•				•											•	
Autoimmune immunomodulation	•	•	•		•	•																				
Inhibition of pathogenic overgrowth				•	•	•				•									•		•	•	•	•	•	
Inactivate microbial toxins																									•	
Increase infection resistance	•	•		•		•		•														•		•	•	
Th1/Th2 immune cell modulation						•				•								•	•			•	•			
Staphylococci inhibition										•								•								
Gut-brain axis support					•									•	•	•	•					•		•		
GABA production						•			•																	
Bone resorption inhibition	•	•	•																							
E. coli inhibition										•				•	•				•			•	•	•	•	
Oxalate degradation						•	•							•												



-.MELISSA ZULLI 3 BANK STREET ASCOT VALE VIC 3032

LACHLAN STACEY 14-Aug-2013 Male

698 FIG TREE POCKET ROAD FIG TREE POCKET QLD 4069

LAB ID : 4026836 UR NO. : 6647919 Collection Date : 23-Sep-2024 Received Date: 24-Sep-2024



4026836


Introduction:

Your gut microbiome is a collective name for the 40 trillion cells and up to 1000 microbial species that include bacteria, viruses, fungi, parasites, and archaea and reside in our gut. The number of gut bacterial cells is approximately equal to the total number of human cells in our body, so if we consider only cell counts, we are only about half human. In terms of gene counts, the microbiome contains about 200 times more genes than the human genome, making bacterial genes responsible for over 99% of our body's gene content! Of all the microbial communities in the human body, the gut microbiome is by far the most dense, diverse, and physiologically important ecosystem to our overall health.

Relative Commensal Abundan	ce Result	Range	Units
Bacteroidetes Phylum	70.193	50.000 - 95.000	%
Firmicutes Phylum	28.752	3.500 - 40.000	%
Proteobacteria Phylum	1.044	0.050 - 12.500	%
Actinobacteria Phylum	0.011	0.001 - 4.818	%
Euryarchaeota Phylum	0.000	0.000 - 0.010	%
Verrucomicrobia Phylum	0.000	0.000 - 2.400	%

Your Phyla:

Healthy Phyla:



References

NOTE: Relative abundance reference ranges have been based on a healthy population study.

King CH, et., al. (2019) Baseline human gut microbiota profile in healthy people and standard reporting template. PLoS One. 2019 Sep 11;14(9):e0206484.

Page 5 of 14 Complete Microbiome Map V2 Lab ID: 4026836 Patient Name: LACHLAN STACEY Printed: 02/Oct/24 10:19



-.MELISSA ZULLI 3 BANK STREET ASCOT VALE VIC 3032

LACHLAN STACEY 14-Aug-2013 Male

698 FIG TREE POCKET ROAD FIG TREE POCKET QLD 4069

LAB ID : 4026836 UR NO. : 6647919 Collection Date : 23-Sep-2024 Received Date: 24-Sep-2024



4026836

ANTIBIOTIC SENSITIVITIES and NATURAL INHIBITORS

K. pneumoniae complex

Antibiotics

Susceptible

Amoxicillin

N/A

Ampicillin

R

Augmentin

S

Ciprofloxacin

S

Norfloxacin

S

Meropenem

S

Cefazolin

N/A

Gentamycin.

S

Trimethoprim/Sulpha

S

Erythromycin

N/A

Penicillin.

N/A

LEGEND

S = Sensitive

R = Resistant

N/A = Not Tested

Inhibitors

Inhibition %

Berberine

60%

Black Walnut

40%

Caprylic Acid

80%

Citrus Seed

60%

Coptis

40%

Garlic-

Golden seal

60%

20%

Oregano

60%

LEGEND

Low Inhibition

High Inhibition

0	20	40	60	80	100



-. MELISSA ZULLI **3 BANK STREET ASCOT VALE VIC 3032**

LACHLAN STACEY 14-Aug-2013 Male

698 FIG TREE POCKET ROAD **FIG TREE POCKET QLD 4069**

LAB ID: 4026836 UR NO.: 6647919 Collection Date : 23-Sep-2024 24-Sep-2024 **Received Date:**



YEAST - SENSITIVITIES and NATURAL ANTIFUNGALS

Antifungals

Fluconazole

Voriconazole

Itraconazole

INHIBITION CATEGORY

Resistant This category indicates that the organism is not inhibited by obtainable levels of the pharmaceutical agent

This category indicates where the minimum inhibition concentrations (MIC) approach obtainable pharmaceutical Intermediate

agent levels and for which response rates may be lower than for susceptible isolates

SDD Susceptible, This category indicates that clinical efficay is achieved when higher than normal dosage of a drug is

Dose Dependent used to achieve maximal concentrations

Susceptible This category indicates that the organisms are inhibited by the usual achievable concentration of the agent NI No Interpretative This category indicates that there are no established guidelines for MIC interpretation for these organisams

Guidelines

Non-absorbed Antifungals

Nystatin

Natural Antifungals

Berberine.

Garlic

Black Walnut.

Citrus Seed.

Coptis.

Golden seal.

Oregano.

LEGEND

Low Inhibition **High Inhibition**

20 40 60 80 100



-.MELISSA ZULLI 3 BANK STREET ASCOT VALE VIC 3032

LACHLAN STACEY 14-Aug-2013 Male

698 FIG TREE POCKET ROAD FIG TREE POCKET QLD 4069

LAB ID : 4026836 UR NO. : 6647919 Collection Date : 23-Sep-2024 Received Date: 24-Sep-2024



4026836

Pathogen Summary:

Macroscopy Comment

BROWN coloured stool is considered normal in appearance.

Faecal Occult Blood Negative:

Faecal occult blood has not been detected in this specimen. If the test result is negative and clinical symptoms persist, additional follow-up testing using other clinical methods is recommended.

Metabolism Comment

In a healthy gut Short Chain Fatty Acids (SCFAs) exhibited in the following proportions; Butyrate, Acetate, Propionate (16%:60%:24%).

The primary SCFAs butyrate, propionate and acetate are produced by predominant commensal bacteria via fermentation of soluble dietary fibre and intestinal mucus glycans.

Key producers of SCFAs include Faecalibacterium prausnitzii, Akkermansia mucinphila, Bacteroides fragilis, Bifidobacterium, Clostridium and Lactobacillus Spp.

The SCFAs provide energy for intestinal cells and regulate the actions of specialised mucosal cells that produce anti-inflammatory and antimicrobial factors, mucins that constitute the mucus barriers, and gut active peptides that facilitate appetite regulation and euglycemia. Abnormal SCFAs may be associated with dysbiosis, intestinal barrier dysfunction and inflammatory conditions.

Page 8 of 14 Complete Microbiome Map V2 Lab ID: 4026836 Patient Name: LACHLAN STACEY Printed: 02/Oct/24 10:19



-.MELISSA ZULLI 3 BANK STREET ASCOT VALE VIC 3032

LACHLAN STACEY 14-Aug-2013 Male

698 FIG TREE POCKET ROAD FIG TREE POCKET OLD 4069

LAB ID: 4026836 UR NO.: 6647919 Collection Date: 23-Sep-2024 Received Date: 24-Sep-2024



4026836

GIT Markers Comment

PANCREATIC ELASTASE: Normal exocrine pancreatic function.

Pancreatic Elastase reflects trypsin, chymotrypsin, amylase and lipase activity.

This test is not affected by supplements of pancreatic enzymes.

Healthy individuals should be producing >500 ug/g of PE-1 under normal/healthy conditions.

PE-1 levels between 200 - 500 ug/g may indicate suboptimal production.

PE-1 levels <200 ug/g indicate clear inadequate production.

The clinician should therefore consider digestive enzyme supplementation if one or more of the following conditions is present: Loose watery stools, Undigested food in the stools, Post-prandial abdominal pain, Nausea or colicky abdominal pain, Gastroesophageal reflux symptoms, Bloating or food intolerance.

Testing performed by chemiluminescence immunosassay (CLIA).

CALPROTECTIN Normal:

Faecal calprotectin values <50 ug/g are not indicative of inflammation in the gastrointestinal tract. Subjects with low faecal calprotectin levels normally do not need to be further investigated by invasive procedures. In patients with strong clinical indications of intestinal inflammation, repeat testing may be useful.

Test performed by Diasorin Liaison XL chemiluminescent immunoassay (CLIA).

SECRETORY IGA NORMAL:

Secretory IgA is within range.

Secretory IgA represents the first line of defence of the gastrointestinal mucosa and is central to the normal function of the gastrointestinal tract as an immune barrier. Review this level with other pathogenic bacteria and normal commensal flora. Lower levels within reference range should be interpreted clinically.

ZONULIN NORMAL:

Zonulin is a protein that modulates intestinal barrier function. This results is considered normal.

beta GLUCURONIDASE ELEVATED:

Beta-glucuronidase is a bacterial enzyme that may limit the body's ability to excrete compounds such as drugs, hormones, and environmental toxins. Certain bacteria may also increase Beta-glucuronidase such as elevated levels of E.coli.

Treatment:

Consider Calcium-D-glucarate which may assist with lowering B-glucuronidase levels. It is also suggested to introduce a low-calorie/vegetarian diet for 4 weeks which may also be beneficial with lowering faecal B-glucuronidase levels. Additionally, one human study has suggested that consuming glucomannan can reduce fecal beta-glucuronidase activity. Glucomannan is a type of prebiotic fiber found in konjac root which is commonly used to make low calorie pasta and noodles.

ELEVATED STEATOCRIT:

The presence of steatorrhea is an indirect indicator of incomplete fat digestion. Consider high dietary fat intake, cholestasis, malabsorption and digestion (diarrhoea, pancreatic or bile salt insufficiency), intestinal dysbiosis, parasites, NSAIDs use, short bowel syndrome, whipple disease, crohn's disease, food allergies & sensitivities.

Treatment:

- o Prebiotic and probiotic supplementation
- o Supplement hydrochloride, digestive enzymes or other digestive aids
- o Investigate underlying causes
- o Investigate food sensitivities and allergies
- o Remove potential irritants
- o Review markers such as pancreatic elastase 1 and calprotectin

Potential Autoimmune Comments

KLEBSIELLA SPECIES ELEVATED:

PHYLUM: Proteobacteria

DESCRIPTION:

Klebsiella is a genus of Gram-negative, oxidase-negative, rod-shaped bacteria that is ubiquitous in the environment and part of the normal intestinal flora. However, they can also behave as opportunistic human pathogens. Overgrowth may cause diarrhea, gas, abdominal pain, and bloating. Klebsiella may cause histamine release and increased intestinal inflammatory activity. It also may be associated with antibiotic-associated haemorrhagic colitis.

Page 9 of 14 Complete Microbiome Map V2 Lab ID: 4026836 Patient Name: LACHLAN STACEY Printed: 02/Oct/24 10:19



-.MELISSA ZULLI 3 BANK STREET ASCOT VALE VIC 3032

LACHLAN STACEY 14-Aug-2013 Male

698 FIG TREE POCKET ROAD FIG TREE POCKET QLD 4069

LAB ID : 4026836 UR NO. : 6647919 Collection Date : 23-Sep-2024 Received Date: 24-Sep-2024



4026836

TREATMENT SUGGESTIONS:

A practitioner may take into consideration a range of patient factors and symptoms to determine if treatment is necessary. Klebsiella appears to thrive in individuals on a high starch diet. Avoiding carbohydrates such as rice, potatoes, flour products and sugary foods may reduce the amount of Klebsiella in the gut. Resistance to common antibiotics is common and the use of herbal antimicrobials oregano (Origanum vulgare), sage (Salvia officinalis) or thyme (Thymus vulgaris) may be effective.

KLEBSIELLA PNEUMONIAE ELEVATED:

PHYLUM: Proteobacteria

DESCRIPTION:

Klebsiella pneumoniae is a gram-negative, encapsulated, non-motile bacterium found in the environment and typically colonizes human mucosal surfaces of the oropharynx and gastrointestinal tract. Increased colonisation causes insult to the intestinal mucosa via the secretion of toxins and subsequent inflammatory response that may lead to inflammation-related gastrointestinal diseases. It Is typically associated with diseases related to upper respiratory tract infection; however, elevated levels may be associated with gastrointestinal diseases such as Irritable bowel disease, Crohn's and ulcerative colitis.

TREATMENT SUGGESTIONS:

Treating K. pneumoniae infections is difficult due to the increased emergence in resistant strains and if treatment is warranted, a combination of antibiotics may be used. Klebsiella appears to thrive in individuals on a high starch diet. Avoiding carbohydrates such as rice, potatoes, flour products and sugary foods may reduce the amount of Klebsiella in the gut. The use of herbal antimicrobials oregano (Origanum vulgare), sage (Salvia officinalis) or thyme (Thymus vulgaris) may also be effective.

Page 10 of 14 Complete Microbiome Map V2 Lab ID: 4026836 Patient Name: LACHLAN STACEY Printed: 02/Oct/24 10:19



-.MELISSA ZULLI 3 BANK STREET ASCOT VALE VIC 3032

LACHLAN STACEY 14-Aug-2013 Male

698 FIG TREE POCKET ROAD FIG TREE POCKET QLD 4069

LAB ID : 4026836 UR NO. : 6647919 Collection Date : 23-Sep-2024 Received Date: 24-Sep-2024



4026836

Normal Bacterial Flora Comment

BACTEROIDES FRAGILIS LOW:

PHYLUM: Bacteroidetes

DESCRIPTION: Bacteroides fragilis is an anaerobic, Gram-negative bacterium. It is part of the normal microbiota of the human colon and is generally commensal. Bacteroides fragilis plays an intricate role in the human colon and usually has a beneficial relationship with the host. Low Bacteroides fragilis levels have been associated with inflammatory bowel disease and Crohn's.

TREATMENT SUGGESTIONS: Treatment may involve the use of probiotics and dietary modification.

BIFIDOBACTERIUM ADOLESCENTIS LOW:

PHYLUM: Actinobacteria

DECCRIPTION

Bifidobacterium adolescentis is an anaerobic species of bacteria found in the gastrointestinal tracts of humans. It is one of the most abundant and prevalent Bifidobacterium species commonly found in adults. It contributes to the production of GABA, a neurotransmitter that plays a role in reducing stress and anxiety. Some strains can synthesise B vitamins, such as folic acid. B. adolescentis enhances the growth of all bifidobacteria.

TREATMENT SUGGESTIONS:

Consider a probiotic supplement containing B. adolescentis and consuming prebiotic-rich foods like garlic, onions, and whole grains. Increase dietary fibre from fruits, vegetables, and legumes, and incorporate fermented foods such as yogurt and kefir.

BIFIDOBACTERIUM BIFIDUM LOW:

PHYLUM: Actinobacteria

DESCRIPTION:

Bifidobacterium bifidum is a Gram-positive, anaerobic bacterium integral to the human gut microbiota, especially in infants. It ferments a variety of carbohydrates, including human milk oligosaccharides, aiding in digestion, and promoting a healthy gut flora. B. bifidum produces short-chain fatty acids that lower gut pH and inhibit pathogenic bacteria while supporting intestinal cells. It also modulates the immune system, enhancing immune responses and reducing inflammation, and strengthens the intestinal barrier. Clinically, B. bifidum has shown promise in alleviating gastrointestinal disorders.

BIFIDOBACTERIUM BREVE LOW:

PHYLUM: Actinobacteria

DESCRIPTION:

Bifidobacterium breve is a Gram-positive, anaerobic bacterium that is commonly found in the human gastrointestinal tract, particularly in the intestines of infants. B. breve is known for its ability to metabolise various carbohydrates, including human milk oligosaccharides, which is essential for the development of a healthy gut flora in newborns.

Studies demonstrate that B. breve exhibits several beneficial properties, including the production of short-chain fatty acids (SCFAs) such as acetate, which contribute to gut health by lowering pH and inhibiting the growth of pathogenic bacteria.

Additionally, B. breve may alleviate symptoms of irritable bowel syndrome (IBS) and improve symptoms of atopic dermatitis.

LACTOBACILLUS ACIDOPHILUS LOW:

PHYLUM: Firmicutes

DESCRIPTION:

Lactobacillus acidophilus is a Gram-positive, rod-shaped, non-spore-forming bacterium commonly found in the human gut and fermented foods. It plays a key role in oxalate degradation, bowel normalisation and may assist patients with bloating.

TREATMENT SUGGESTIONS:

Consider probiotic supplementation containing L. acidophilus.

LACTOBACILLUS PLANTARUM LOW:

PHYLUM: Firmicutes

DESCRIPTION:



-.MELISSA ZULLI 3 BANK STREET ASCOT VALE VIC 3032

LACHLAN STACEY 14-Aug-2013 Male

698 FIG TREE POCKET ROAD FIG TREE POCKET QLD 4069

LAB ID : 4026836 UR NO. : 6647919 Collection Date : 23-Sep-2024 Received Date: 24-Sep-2024



4026836

Lactobacillus plantarum is a Gram-positive, non-spore-forming, rod-shaped bacterium. L. plantarum plays a crucial role in gut health by enhancing intestinal barrier function, modulating the immune system, and inhibiting pathogenic bacteria. Additionally, it is beneficial for conditions such as irritable bowel syndrome, ulcerative colitis, and high cholesterol.

TREATMENT SUGGESTIONS:

Consider probiotic supplementation containing L. plantarum.

LACTOBACILLUS RHAMNOSUS LOW:

PHYLUM: Firmicutes

DESCRIPTION:

Lactobacillus Rhamnosus is a Gram-positive anaerobic bacterium and is one of the most widely used probiotic strains, of which various health effects are well documented including the prevention and treatment of gastro-intestinal infections and diarrhea and even preventing certain allergic symptoms.

Decreased Lactobacillus rhamnosus colonisation has been shown to decrease gastro-intestinal health, increasing the risk of gastro-intestinal infections and diarrhea as well as extra-intestinal infections including oral and respiratory health. Studies have also revealed that chronic psychological stress and alcohol use may be associated with a decrease in Lactobacillus species, as well as antibiotic / medication use.

TREATMENT SUGGESTIONS: Treatment may involve the use of Lactobacillus containing probiotics and treatment of any intestinal infections.

LACTOBACILLUS SALIVARIUS LOW:

PHYLUM: Firmicutes

DESCRIPTION:

Lactobacillus salivarius is a Gram-positive, rod-shaped, non-spore-forming bacterium predominantly found in the human oral cavity, gastrointestinal tract, and vagina. It plays a significant role in maintaining oral and gut health by producing lactic acid and bacteriocins, which inhibit the growth of pathogenic bacteria. L. salivarius enhances gut barrier function, modulates the immune system, and helps in the digestion of proteins and complex carbohydrates. It has been studied for its potential benefits in managing conditions such as irritable bowel syndrome (IBS), periodontal disease, and atopic dermatitis, highlighting its importance in promoting overall health and preventing infections.

TREATMENT SUGGESTIONS:

Consider L. salivarius as a probiotic strain which may improve intestinal permeability and immune response.

OXOLOBACTER FORMIGENES LOW:

PHYLUM: Proteobacterium

DESCRIPTION:

Oxalobacter formigenes is a Gram negative oxalate-degrading anaerobic bacterium. Oxolate is formed in the liver by amino acid catabolism as well as present in a wide range of foods including tea, coffee, chocolate and certain fruits and vegetables. High concentration of oxalate in the urine is related to the potential formation of calcium oxalate kidney stones. Oxolobacter Formigenes is the main known bacterial species involved in oxalate degradation in the gut and maintains oxalate homeostasis. Levels of O. Formigenes tends to decrease with age as well as with the use of antibiotics or other drugs. Low levels may be associated with calcium oxide stone formation, inflammatory bowel disease or Crohn's.

TREATMENT SUGGESTIONS:

Treatment options include probiotic treatment and low oxalate diet modification. Urinary oxalate levels may also need to be investigated.

AKKERMANSIA MUCINIPHILA LOW:

PHYLUM: Verrucomicrobia

DESCRIPTION:

Akkermansia muciniphila is a Gram-negative, strictly anaerobic, non-motile bacterium, often considered a human intestinal symbiont. There is growing evidence to suggest that the prevalence of this bacteria is associated with intestinal homeostasis, immunity, and a healthy gut. Decreased colonisation levels may be associated with obesity, type 2 diabetes, and inflammation.

TREATMENT SUGGESTIONS: Treatment may involve the use of probiotics, treatment of any intestinal infections and dietary



-.MELISSA ZULLI 3 BANK STREET ASCOT VALE VIC 3032

modification.

LACHLAN STACEY 14-Aug-2013 Male

698 FIG TREE POCKET ROAD FIG TREE POCKET QLD 4069

LAB ID: 4026836 UR NO.: 6647919 Collection Date: 23-Sep-2024 Received Date: 24-Sep-2024



1026836



-.MELISSA ZULLI 3 BANK STREET ASCOT VALE VIC 3032

LACHLAN STACEY 14-Aug-2013 Male

698 FIG TREE POCKET ROAD FIG TREE POCKET QLD 4069

LAB ID : 4026836 UR NO. : 6647919 Collection Date : 23-Sep-2024 Received Date: 24-Sep-2024



4026836

The Four "R" Treatment Protocol

	Using a course of antimicrobial, antibacterial,	ANTIMICROBIAL	Oil of oregano, berberine, caprylic acid
	antiviral or anti parastic therapiesin cases where organisms are present. It may	ANTIBAC TERIAL	Liquorice, zinc camosine, mastic gum, tribulus, berberine, black walnut, caprylic acid, oil of oregano
REMOVE	also be necessary to remove offending foods, gluten, or	ANTIFUNGAL	Oil of oregano, caprylic acid, berberine, black walnut
	medication that may be acting as antagonists.	ANTIPARASTIC	Artemesia, black walnut, berberine, oil of oregano
	Consider testing IgG96 foods as a tool for removing offending foods.	ANTIVIRAL	Cat's claw, berberine, echinacea, vitamin C, vitamin D3, zinc, reishi mushrooms
		BIOFILM	Oil of oregano, protease
REPLACE	In cases of maldigestion or malabsorption, it may be necessary to restore proper digestion by supplementing with digestive enzymes.	DIGESTIVE SUPPORT	Betaine hydrochloride, tilactase, amylase, lipase, protease, apple cider vinegar, herbal bitters
ш	Recolonisation with healthy, beneficial bacteria.	PREBIOTICS	Sippery elm, pectin, larch arabinogalactans
RENOCULATE	Supplementation with probiotics, along with the use of prebiotics helps re-establish the proper microbial balance.	PROBIOTICS	Bifidobacterium animalis sup lactise, lactobacillus acidophilus, lactobacillus plantarum, lactobacillus casei, bifidobacterium breve, bifidobacterium bifidum, bifidobacterium longum, lactobacillus salivarius sep salivarius, lactobacillus paracasei, lactobacillus rhamnosus, Saccaromyces boulardii
EBALANCE	Restore the integrity of the gut mucosa by giving support to healthy mucosal cells, as well as immune support. Address whole	INTESTINAL MUCOSA IMMUNE SUPPORT	Saccaromyces boulardii, lauric acid
₩ ₩	body health and lifestyle factors so asto prevent future GI dysfunction.	INTESTINAL BARRIER REPAIR	L-Glutamine, a loe vera, liquorice, marshmallow root, okra, quercetin, slippery elm, zinc camosine, Saccaromyces boulardii, omega 3 essential fatty acids, B vitamins
REPAIR		SUPPORT CONSIDERATION	Seep, diet, exercise, and stress management